See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Baseball
Natural Disasters
Stock Markets
Social Media
Tariffs
UK Economy
Taxes
Soccer
Donald Trump
Education
Senate
Artificial Intelligence
Published • loading... • Updated

Refining chimeric antigen receptors via barcoded protein domain combination pooled screening

Summary by ScienceDirect
Chimeric antigen receptor (CAR)-T cells represent a promising frontier in cancer immunotherapy. However, the current process for developing new CAR co…

4 Articles

All
Left
Center
Right
ScienceDirectScienceDirect

Refining chimeric antigen receptors via barcoded protein domain combination pooled screening

Chimeric antigen receptor (CAR)-T cells represent a promising frontier in cancer immunotherapy. However, the current process for developing new CAR co…

·Amsterdam, Netherlands
Read Full Article
BIOENGINEER.ORGBIOENGINEER.ORG

Scientists Utilize Machine Learning to Create Predictive Test for

In a groundbreaking advancement in the field of oncology, researchers from City of Hope and Memorial Sloan Kettering Cancer Center (MSK) have developed a powerful new tool that leverages machine learning to predict how non-Hodgkin lymphoma (NHL) patients will respond to chimeric antigen receptor (CAR) T cell therapy before the treatment begins. This tool, known as InflaMix (Inflammation Mixture Model), represents a significant stride forward in …

Read Full Article
onclive.comonclive.com

Optimized Tandem CD19/CD20–Directed CAR T Plus ASCT Elicits Durable Responses in R/R B-Cell Lymphomas

Higher CR rates were achieved with the tandem CAR T-cell infusion plus ASCT vs the infusion alone in patients with relapsed/refractory B-cell lymphoma.

Read Full Article
cancernetwork.comcancernetwork.com

Transplant-Eligible, CAR T Considered: How Do We Decide?

Panelists discuss how, when selecting among chimeric antigen receptor T-cell (CAR T) therapies, medical professionals typically consider several key factors: the specific cancer type and its CD19/BCMA expression, FDA-approved indications for each therapy, the patient’s prior treatments and response history, the therapy’s documented efficacy and safety profile, manufacturing time and availability, and center-specific experience with different pro…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

cancernetwork.com broke the news in on Monday, March 31, 2025.
Sources are mostly out of (0)

Similar News Topics

NHL

NHL

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal